This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Zengnan Mo
the First Affiliated Hospital of Guangxi Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The IGF2BP3 can affect cancer cells through the regulation of m6A. In this study, we combined the RNA sequencing and the RNA methylation sequencing to investigate the role and the mechanism of the IGF2BP3 in bladder cancer.TCGA data showed that the intersection genes of RBP differentially expressed and RBP involved in m6A modification were IGF2BP1 and IGF2BP3, only IGF2BP3 was significantly associated with short survival time (P < 0.01). Then immunohistochemistry and qRT-PCR detection showed that IGF2BP3 is highly expressed in bladder cancer (P < 0.05). The T24 knockout IGF2BP3 cell line was successfully constructed, with cell proliferation decreased and the apoptosis increased (P < 0.05). RNA sequencing results of clinical bladder tissue from 53 cases showed that the expression of IGF2BP3 samples were associated with the high levels of proliferation-related genes. The analysis of combined RNA and M6a level showed the differential genes related to cell growth and proliferation: SPHK1, POMT2, MRPS18a in T24 and T24-KO. Our study suggests that the IGF2BP3 is highly expressed in bladder cancer and related to tumor metastasis and invasion, the IGF2BP3 expression is related to cell proliferation genes, which affects the growth, proliferation, and apoptosis of T24 cells, and SpHK1, POMT2, and MRPS18a may be potential targets of IGF2BP3.
Keywords
bladder cancer, IGF2BP3
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
No competing interests reported.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 19 May, 2021
No community comments so far
Reviews received
Received 09 Jun, 2021
Reviewers agreed
On 26 May, 2021
Reviewers invited
Invitations sent on 26 May, 2021
Editor assigned
On 26 May, 2021
Editor invited
On 19 May, 2021
Submission checks complete
On 18 May, 2021
First submitted
On 14 Apr, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Zengnan Mo
the First Affiliated Hospital of Guangxi Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 19 May, 2021
No community comments so far
Reviews received
Received 09 Jun, 2021
Reviewers agreed
On 26 May, 2021
Reviewers invited
Invitations sent on 26 May, 2021
Editor assigned
On 26 May, 2021
Editor invited
On 19 May, 2021
Submission checks complete
On 18 May, 2021
First submitted
On 14 Apr, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The IGF2BP3 can affect cancer cells through the regulation of m6A. In this study, we combined the RNA sequencing and the RNA methylation sequencing to investigate the role and the mechanism of the IGF2BP3 in bladder cancer.TCGA data showed that the intersection genes of RBP differentially expressed and RBP involved in m6A modification were IGF2BP1 and IGF2BP3, only IGF2BP3 was significantly associated with short survival time (P < 0.01). Then immunohistochemistry and qRT-PCR detection showed that IGF2BP3 is highly expressed in bladder cancer (P < 0.05). The T24 knockout IGF2BP3 cell line was successfully constructed, with cell proliferation decreased and the apoptosis increased (P < 0.05). RNA sequencing results of clinical bladder tissue from 53 cases showed that the expression of IGF2BP3 samples were associated with the high levels of proliferation-related genes. The analysis of combined RNA and M6a level showed the differential genes related to cell growth and proliferation: SPHK1, POMT2, MRPS18a in T24 and T24-KO. Our study suggests that the IGF2BP3 is highly expressed in bladder cancer and related to tumor metastasis and invasion, the IGF2BP3 expression is related to cell proliferation genes, which affects the growth, proliferation, and apoptosis of T24 cells, and SpHK1, POMT2, and MRPS18a may be potential targets of IGF2BP3.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...